Compare BCML & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCML | PLYX |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.6M | 271.8M |
| IPO Year | 2018 | N/A |
| Metric | BCML | PLYX |
|---|---|---|
| Price | $30.40 | $3.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $34.00 | $10.00 |
| AVG Volume (30 Days) | 37.3K | ★ 108.5K |
| Earning Date | 04-23-2026 | 05-22-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | ★ 3.81 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.71 | N/A |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $40.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.06 | $2.20 |
| 52 Week High | $33.15 | $9.18 |
| Indicator | BCML | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 35.36 |
| Support Level | $27.23 | $2.58 |
| Resistance Level | $30.74 | $7.29 |
| Average True Range (ATR) | 0.63 | 0.54 |
| MACD | 0.11 | -0.19 |
| Stochastic Oscillator | 66.74 | 19.78 |
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses, and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services. The Company operates as one reportable segment: banking operations.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.